Published March 19, 2021 | Version v1
Journal article Open

Neurodegenerative phosphoprotein signaling landscape in models of SCA3

  • 1. Institute of Medical Genetics and Applied Genomics, University of Tuebingen, Calwerstrasse 7, 72076, Tuebingen, Germany
  • 2. Center for Applied Proteomics and Molecular Medicine, College of Science, George Mason University, Manassas, VA, USA

Description

Spinocerebellar ataxia type 3 (SCA3) is a rare neurodegenerative disorder resulting from an aberrant expansion of a polyglutamine stretch in the ataxin-3 protein and subsequent neuronal death. The underlying intracellular signaling pathways are currently unknown. We applied the Reverse-phase Protein MicroArray (RPMA) technology to assess the levels of 50 signaling proteins (in phosphorylated and total forms) using three in vitro and in vivo models expressing expanded ataxin-3: (i) human embryonic kidney (HEK293T) cells stably transfected with human ataxin-3 constructs, (ii) mouse embryonic fibroblasts (MEF) from SCA3 transgenic mice, and (iii) whole brains from SCA3 transgenic mice. All three models demonstrated a high degree of similarity sharing a subset of phosphorylated proteins involved in the PI3K/AKT/GSK3/mTOR pathway. Expanded ataxin-3 strongly interfered (by stimulation or suppression) with normal ataxin-3 signaling consistent with the pathogenic role of the polyglutamine expansion. In comparison with normal ataxin-3, expanded ataxin-3 caused a pro-survival stimulation of the ERK pathway along with reduced pro-apoptotic and transcriptional responses.

Files

13041_2020_Article_723.pdf

Files (1.6 MB)

Name Size Download all
md5:0ccfd429973594a217ead5f44525f927
31.0 kB Download
md5:6e7da4647e0eb4e825389826ca04089c
1.6 MB Preview Download
md5:3d320641c15350fe4855701a5680d6a9
14.7 kB Download

Additional details

Funding

TREATPOLYQ – TreatPolyQ – Industrial Academic Initial Training Network towards treatment of Polyglutamine Diseases. 264508
European Commission